| | Identification | Back Directory |  | [Name] 
 Anavex 2-73
 |  | [CAS] 
 195615-84-0
 |  | [Synonyms] 
 CS-2759
 Anavex 2-73
 Blarcamesine
 Anavex2-73 HCl
 AVex-73 hydrochL
 AE-37 HYDROCHLORIDE
 AN2/AVEX-73 HCL SALT
 AVex-73 hydrochloride
 Anavex 2-73(ANAVEX2-73)
 Blarcamesine hydrochloride
 AVex-73 hydrochloride(AE-37)
 AN2/AVex-73 hydrochloride salt
 Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride salt
 AE-37; AVEX-73; ANAVEX-2-73; ANAVEX-273; AE37; AVEX73; ANAVEX273; AE 37; AVEX 73; ANAVEX 2 73; ANAVEX 273; BLARCAMESINE
 |  | [Molecular Formula] 
 C19H24ClNO
 |  | [MDL Number] 
 MFCD30146449
 |  | [MOL File] 
 195615-84-0.mol
 |  | [Molecular Weight] 
 317.86
 | 
 | Chemical Properties | Back Directory |  | [Melting point ] 
 165 - 168°C
 |  | [storage temp. ] 
 -20°C Freezer, Under inert atmosphere
 |  | [solubility ] 
 DMSO (Slightly), Methanol (Slightly)
 |  | [form ] 
 Solid
 |  | [color ] 
 White to Off-White
 |  | [InChI] 
 InChI=1S/C19H23NO.ClH/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17;/h3-12,18H,13-15H2,1-2H3;1H
 |  | [InChIKey] 
 FEQOLYDPQKHFTD-UHFFFAOYSA-N
 |  | [SMILES] 
 C(C1CCOC1(C1C=CC=CC=1)C1C=CC=CC=1)N(C)C.Cl
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine Hydrochloride is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety, or agitation.Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine Hydrochloride is also used in pharmacological studies such as the anti-amnesic and neuroprotective potentials of mixed muscarinic receptor/σ1 ligand ANAVEX2-73 as novel aminotetrahydrofuran deriv.
 |  | [in vivo] 
 
 The pre-administration of Blarcamesine leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg[1]. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1?mg/kg. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1?mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser9 phosphorylation induced by the peptide at 0.3 and 1?mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ25-35-induced increase in Aβ1-42 content, with a significant effect at the highest dose tested[2]. |  | [IC 50] 
 Sigma 1 Receptor
 | 
 | 
                    
                        
                            | Company Name: | BOC Sciences |  
                            | Tel: | 1-631-485-4226; 16314854226 |  
                            | Website: | https://www.bocsci.com |  |